PLAB vs PTRN

PLAB presents a dichotomy between a pristine balance sheet and concerning valuation/sentiment signals. While the Piotroski F-Score of 4/9 indicates stable health and the company maintains zero debt with exceptional liquidity, the stock's 157.8% one-year rally has outpaced its modest 6-8% growth rates. The current price of $45.84 is trading near its growth-based intrinsic value ($47.27) but significantly above its defensive Graham Number ($33.13). Heavy insider selling by the CEO and President, coupled with a high PEG ratio of 2.64, suggests the stock is currently overextended.

PTRN presents a stark contrast between strong growth metrics and poor operational health, as evidenced by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 40.30% and a reasonable Forward P/E of 23.01, its net profit margins are razor-thin at 0.65%. The balance sheet is clean with very low debt (D/E 0.05) and strong liquidity (Current Ratio 2.34), but the lack of operational efficiency drags down the deterministic health scores. The stock is currently viewed as a speculative growth play with a significant gap between its current price and analyst targets.